BioMarin Pharmaceutical (NASDAQ:BMRN) vs. Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Comparison

BioMarin Pharmaceutical (NASDAQ:BMRN) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Profitability

This table compares BioMarin Pharmaceutical and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Institutional & Insider Ownership

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for BioMarin Pharmaceutical and Oramed Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1	6	15	1	2.70
Oramed Pharmaceuticals	0	1	0	0	2.00

BioMarin Pharmaceutical currently has a consensus price target of $89.17, suggesting a potential upside of 39.46%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than Oramed Pharmaceuticals.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and Oramed Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22 billion	3.84	$348.90 million	$0.37	172.81
Oramed Pharmaceuticals	$2.00 million	98.59	$64.05 million	$4.12	1.15

BioMarin Pharmaceutical has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Summary

BioMarin Pharmaceutical beats Oramed Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.